Connie J Kim1, Sharon L Walmsley1,2, Janet M Raboud1,2, Colin Kovacs3, Bryan Coburn1,2, Rodney Rousseau2, Robert Reinhard4, Ron Rosenes5, Rupert Kaul1,2. 1. a Toronto General Research Institute , University Health Network , Toronto , Canada. 2. c Department of Immunology, Dalla Lana School of Public Health, and Laboratory Medicine and Pathobiology , University of Toronto , Toronto , Canada. 3. b Maple Leaf Medical Clinic , Toronto , Canada. 4. d Public/Global Health Consultant , Toronto , ON , Canada. 5. e Community Health Advocate and Consultant , Toronto , ON , Canada.
Abstract
OBJECTIVES: Despite substantial improvements in HIV outcomes with combination antiretroviral therapy (cART), morbidity and mortality remain above population norms. The gut mucosal immune system is not completely restored by cART, and the resultant microbial translocation may contribute to chronic inflammation, inadequate CD4 T-cell recovery, and increased rates of serious non-AIDS events. Since the microbial environment surrounding a CD4 T cell may influence its development and function, we hypothesize that probiotics provided during cART might reduce inflammation and improve gut immune health in HIV-positive treatment-naïve individuals (PROOV IT I) and individuals with suboptimal CD4 recovery on cART (PROOV IT II). METHODS: These prospective, double-blinded, randomized, placebo-controlled, multicenter pilot studies will assess the impact of the probiotic Visbiome at 900 billion bacteria daily. Forty HIV positive cART-naïve men will be randomized in the PROOV IT I study, coincident with antiretroviral initiation, and be followed for 24 weeks. In PROOV IT II, 36 men on cART, but with a CD4 T-cell count below 350 cells/mm(3) will be followed for 48 weeks. The primary outcome for both studies is the comparison of blood CD8 T-cell immune activation. Secondary analyses will include comparison of blood inflammatory biomarkers, microbial translocation, blood and gut immunology and HIV levels, the bacterial community composition, diet, intestinal permeability, and the safety, adherence and tolerability of the study product. DISCUSSION: These studies will evaluate the ability of probiotics as a safe and tolerable therapeutic intervention to reduce systemic immune activation and to accelerate gut immune restoration in people living with HIV.
RCT Entities:
OBJECTIVES: Despite substantial improvements in HIV outcomes with combination antiretroviral therapy (cART), morbidity and mortality remain above population norms. The gut mucosal immune system is not completely restored by cART, and the resultant microbial translocation may contribute to chronic inflammation, inadequate CD4 T-cell recovery, and increased rates of serious non-AIDS events. Since the microbial environment surrounding a CD4 T cell may influence its development and function, we hypothesize that probiotics provided during cART might reduce inflammation and improve gut immune health in HIV-positive treatment-naïve individuals (PROOV IT I) and individuals with suboptimal CD4 recovery on cART (PROOV IT II). METHODS: These prospective, double-blinded, randomized, placebo-controlled, multicenter pilot studies will assess the impact of the probiotic Visbiome at 900 billion bacteria daily. Forty HIV positive cART-naïve men will be randomized in the PROOV IT I study, coincident with antiretroviral initiation, and be followed for 24 weeks. In PROOV IT II, 36 men on cART, but with a CD4 T-cell count below 350 cells/mm(3) will be followed for 48 weeks. The primary outcome for both studies is the comparison of blood CD8 T-cell immune activation. Secondary analyses will include comparison of blood inflammatory biomarkers, microbial translocation, blood and gut immunology and HIV levels, the bacterial community composition, diet, intestinal permeability, and the safety, adherence and tolerability of the study product. DISCUSSION: These studies will evaluate the ability of probiotics as a safe and tolerable therapeutic intervention to reduce systemic immune activation and to accelerate gut immune restoration in people living with HIV.
Authors: Ó Moreno-Pérez; L Giner; S Reus; V Boix; R Alfayate; R Frances; E Merino; A Pico; J Portilla Journal: Eur J Clin Microbiol Infect Dis Date: 2017-12-02 Impact factor: 3.267
Authors: Zheng Wang; Mykhaylo Usyk; Christopher C Sollecito; Yunping Qiu; Jessica Williams-Nguyen; Simin Hua; Ana Gradissimo; Tao Wang; Xiaonan Xue; Irwin J Kurland; Klaus Ley; Alan L Landay; Kathryn Anastos; Rob Knight; Robert C Kaplan; Robert D Burk; Qibin Qi Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 20.999
Authors: George M Carter; Aryan Esmaeili; Hardikkumar Shah; Debbie Indyk; Matthew Johnson; Michael Andreae; Henry S Sacks Journal: Open Forum Infect Dis Date: 2016-07-29 Impact factor: 3.835